T he Ewing family of tumors is a group of primary bone and soft-tissue tumors that includes classic Ewing sarcoma, peripheral primitive neuroectodermal tumor, and Askin tumor of the chest wall. The incidence of Ewing-family tumors peaks in the second decade of life, is slightly more common in males, and commonly arises in the extremities [1] [2] [3] [4] [5] [6] [7] , with the pelvis being the single most common site 8 . There is limited published literature describing the results of treating patients with an extremity Ewing-family tumor [9] [10] [11] [12] ; most of the reported results have been included as part of clinical Disclosure: None of the authors received payments or services, either directly or indirectly (i.e., via his or her institution), from a third party in support of any aspect of this work. None of the authors, or their institution (s), have had any financial relationship, in the thirty-six months prior to submission of this work, with any entity in the biomedical arena that could be perceived to influence or have the potential to influence what is written in this work. Also, no author has had any other relationships, or has engaged in any other activities, that could be perceived to influence or have the potential to influence what is written in this work. The complete Disclosures of Potential Conflicts of Interest submitted by authors are always provided with the online version of the article. trials or single-institution studies of Ewing-family tumors including all sites 1, 3, 5, 6, [13] [14] [15] [16] [17] [18] . In these studies, patients with extremity Ewing-family tumors were treated over a long span of time and with different combinations of treatment modalities.
We report the results of 158 cases of extremity Ewingfamily tumor treated at our institute over the last eight years with a uniform chemotherapy protocol. The objective of this study was to discuss clinicopathological features, outcomes, and prognostic factors that influence survival and local tumor control in patients with an extremity Ewing-family tumor.
Materials and Methods Patients
T his study involved review of data on all patients with a proven diagnosis of Ewing-family tumor who were treated in our department from June 2003 to November 2011, with data from January 2011 to November 2011 collected prospectively. Tumors arising from long and short bones of the upper and lower limbs (including the hands and feet) were included. Baseline clinicopathological features, results of the metastatic work-up, treatment modalities, treatmentrelated grade-3 or 4 toxicity (according to the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 19 ), and outcome data were collected. Ethical clearance was obtained from our institutional ethical review committee. Informed consent was obtained from the patients (or guardian if the patient was a minor) who were enrolled prospectively. No informed consent was obtained for retrospective cases from 2003 through 2010, as these cases were studied via a file review. The ethical review committee was aware of this, and they approved the protocol.
Diagnostic Work-up
All patients underwent biopsy (Tru-cut or incisional) of the primary lesion and all patients had histopathological review with confirmation of the diagnosis of Ewing-family tumor before being included in this study. Diagnosis of Ewingfamily tumor required the presence of a small blue round-cell tumor and positive immunohistochemical staining for CD99 (MIC2) and/or synaptophysin or chromogranin. Other round-cell tumors were ruled out by stains for leukocyte common antigen, desmin, and myogenin. Evaluation for translocation (t [11;22] [q24;q11.2-12]) was not performed in this cohort. All patients had computed tomography (CT) or magnetic resonance imaging (MRI) of the affected extremity, and all patients underwent a metastatic work-up including bone scan, CT of the chest, and bone marrow biopsy.
Treatment and Response Evaluation
The treatment protocol consisted of three phases: neoadjuvant chemotherapy for nine to twelve weeks, local therapy in the form of either surgical resection or radical radiation therapy, and then adjuvant chemotherapy. . Radiation therapy was administered at a dose of 55 to 65 Gy for local control without surgery. The disease response was evaluated with use of CT scan or MRI after neoadjuvant chemotherapy and after completion of local therapy. Complete remission, partial response, stable disease, and progressive disease were defined according to RECIST (response evaluation criteria in solid tumors) criteria 22 for the soft-tissue component of the primary lesion as well as non-osseous metastases. Serial radionuclide bone scans was used for bone metastases. All patients without metastases underwent local therapy if they were in complete remission or had a partial response or stable disease after neoadjuvant chemotherapy, whereas all patients with metastases received local therapy if they were in complete remission or had a partial response at the primary tumor site and the site of the metastases. The choice of local therapy was made on an individual basis depending on the primary tumor site and the resectability of the tumor after neoadjuvant chemotherapy with care taken to avoid longterm morbidity and disfigurement. Surgery was preferred wherever wide local excision was possible with clear surgical margins and without mutilating surgery; the decision for surgical resection was made by the treating surgeon and the patient. In general, patients with pathological evidence of complete remission were not subjected to adjuvant radiation therapy, although decisions regarding adjuvant radiation therapy were individualized. All surgically resected tissue blocks were reviewed to assess the histological response to neoadjuvant chemotherapy. A poor histological response was defined as necrosis of <90% of the tumor specimen. After local therapy, all patients received adjuvant chemotherapy for forty-eight weeks with the chemotherapy agents, doses, and schedule similar to those used for the neoadjuvant chemotherapy.
Statistical Analysis
Descriptive statistics were used for demographic and clinical characteristics. A chi-square or Fisher exact test was used to detect associations between qualitative variables. The Student t test or Wilcoxon rank-sum test was applied to compare between categorical and continuous variables. Survival was estimated with the Kaplan-Meier method, and survival estimates were compared by using the log-rank test. Data were censored on November 30, 2012. Patients who were lost to follow-up were censored at the date of last contact/follow-up. Patients who were alive on November 30, 2012, were censored for overall survival analysis.
The Cox proportional hazard model was used in univariate analysis to detect outcome differences between groups. Stepwise multivariate Cox regression analysis was done to identify the predictors of outcome. Factors with significance (p £ 0.1) in the univariate analysis were entered into multivariate analysis. Eventfree survival was calculated from the date of diagnosis to the date of disease recurrence or progression, or death from any cause. Overall survival was calculated from the date of diagnosis to the date of death from any cause. Combined local and distant-site failures were considered to be local failure for analysis of the local control rate. Patients who were lost to follow-up or who had abandoned treatment were also included in the event-free survival and overall survival analyses, and the outcomes for these patients were confirmed by telephone contact. Treatment abandonment was included in the survival analysis in the present study as it has been proposed that patients who do not comply with or who abandon treatment be included in survival analysis for studies from developing nations to provide a true picture of outcomes from these countries 23 .
STATA/SE 9.0 (StataCorp, College Station, Texas) was used for statistical analysis.
Source of Funding
There was no external funding source for this study.
Results

Clinicopathological Profile
T he clinical findings are summarized in the Appendix. During the years of the study, 403 patients with a Ewing-family tumor were registered at our center, and per our intention-to-treat analysis 374 patients were available for survival analysis. Of the 403 registered patients, 165 (41%) had a Ewing-family tumor of an extremity. Seven patients did not receive therapy; thus, 158 patients were analyzed.
Treatment
All 158 patients underwent neoadjuvant chemotherapy, and a median of six cycles (range, two to fifteen cycles) were administered. Twenty-nine patients discontinued neoadjuvant chemotherapy; seventeen of them had a partial response, eight had stable disease, and four were not evaluated. Twenty-nine patients had progressive disease while receiving neoadjuvant chemotherapy.
Two patients died of febrile neutropenia. Thus, ninety-eight patients (62%) received local therapy: surgery was performed in fifty-seven patients (of whom twenty-two received adjuvant radiation therapy), and radical radiation therapy was administered to forty-one patients. Five of the fifty-seven patients in the surgery group had a positive surgical margin. Radiation therapy was given at a median dose of 45 Gy (range, 40 to 60 Gy), with 1.8 to 2 Gy given per day, five days a week, over five to six weeks. While receiving local treatment, four patients had progressive disease and four patients were lost to follow-up; one had complete remission, two had a partial response, and one patient did not return for follow-up after surgery. Thus, the remaining ninety patients received adjuvant chemotherapy (Fig. 1 ). Four patients with baseline metastases underwent high-dose chemotherapy (high-dose busulphan and/or melphalan) with autologous stem-cell transplantation.
Treatment Toxicity
Fifty-one patients (32%) had treatment-related toxicity, including sepsis/febrile neutropenia (forty-four patients), hemorrhagic cystitis (seven), viral hepatitis (one), and dengue shock syndrome (one). Five patients died of febrile neutropenia, and one patient died due to hemorrhagic cystitis with febrile neutropenia. There was no recordable grade-3 or 4 toxicity with radiation therapy.
Response to Neoadjuvant Chemotherapy and Local Therapy
Of the 158 patients, 150 underwent reevaluation after neoadjuvant chemotherapy (six discontinued treatment and two died of sepsis). The reevaluation demonstrated complete remission in thirteen patients, a partial response in ninety-four, stable disease in fourteen, and progressive disease in twenty-nine, with an overall disease-response rate of 71% (107 of 150). Of these 150 patients, ninety-eight received local treatment; fifty-two did not have local treatment (twenty-nine had progressive disease and twentythree-fifteen with a partial response and eight with stable disease-were lost to follow-up). Of the fifty-seven patients who underwent surgery as local therapy, forty-five had limb salvage therapy with reconstruction performed with either autologous bone graft or a metallic prosthesis. One patient did not return for follow-up after surgery. Of the remaining ninetyseven patients, sixty had complete remission after the local therapy, twenty-eight had a partial response, five had stable Flow diagram showing treatment and outcomes of the study patients. EFT = Ewing-family tumor, LFU = lost to follow-up, CR = complete remission, PR = partial response, PD = progressive disease, N = number, and defaulted = did not return for further evaluation or treatment. 
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disease, and four had progressive disease, for an overall response rate of 91% (eighty-eight of ninety-seven). Four patients were lost to follow-up after local therapy and did not receive adjuvant chemotherapy. Thus, the remaining ninety patients received adjuvant chemotherapy, and seventy-two patients received all scheduled cycles of chemotherapy (for a total of forty-eight weeks).
Treatment Failure and Outcome
Treatment failure was observed in eighty-three patients (53%): twenty-two had recurrence after having had complete remission, and sixty-one had progressive disease during or after therapy (after neoadjuvant chemotherapy in twenty-nine, after local therapy in four, and during or after adjuvant chemotherapy in twenty-eight). The site of treatment failure was local only in twenty-eight patients, distant metastasis in thirty patients, and both in twenty-five. The median time to local failure was 14.3 months (range, 2.5 to thirty-eight months).
At the time of analysis, forty-one patients (26%) were alive: thirty-seven of them had complete remission; two, a partial response; and two, progressive disease. Although the event-free survival and local control rates could be assessed for all patients, some patients did not opt for a salvage therapy after being diagnosed with progressive disease; thus, the final survival status of sixty-five patients (41%) could not be assessed for overall survival (twenty-nine were lost to follow-up during or after therapy and thirty-six had progressive disease). Fifty-two patients (33%) died during or after treatment: forty of them had progressive disease, six died of treatment-related toxicity, and six died at home of an unknown cause.
After a median duration of follow-up of 24.3 months (range, 1.6 to ninety-seven months), the estimated five-year event-free survival, overall survival, and local control rates (and standard error) were 24.1% ± 4.3%, 43.5% ± 6%, and 55% ± 6.8%, respectively, for the entire cohort, and 36.4% ± 6.2%, 57.6% ± 7.4%, and 58.2% ± 7.9%, respectively, in the group without metastasis at the time of presentation (n = 89).
Metastatic Disease
Sixty-nine (44%) of the patients had metastasis at baseline (lung only in twenty-three, bone only in fifteen, bone marrow only in six, and a combination of these in twenty-five). Patients with metastatic disease had a larger mean tumor size (11.6 cm versus 9.4 cm; p = 0.02), but a comparable mean symptom duration (7.5 months versus 7.2 months; p = 0.79). All patients received neoadjuvant chemotherapy, which achieved an overall response rate of 52% (complete remission in three and a partial response in thirty, out of sixty-four evaluable), whereas only thirty patients received local therapy (radiation therapy only in twenty-two, surgery with radiation therapy in five, and surgery only in three). The patients with metastasis had a higher rate of systemic symptoms (70% compared with 32%; p < 0.001) and lower albumin levels (median, 4.1 g/dL compared with 4.5 g/dL; p = 0.003). At the time of analysis, seven patients were alive (unknown status for thirty-three [lost to follow-up]), for fiveyear event-free survival, overall survival, and local control rates of 8.9% ± 4.5%, 21.1% ± 8.8%, and 49.3% ± 12.2%, respectively. The reason why so many patients were lost to follow-up may be that most of the patients had a higher burden of disease, and they may have progressed on treatment, or had treatmentrelated toxicity, and thus not returned for any further treatment.
Univariate Analysis of Prognostic Factors
Entire Cohort
Univariate analysis showed that event-free survival was adversely affected by the presence of systemic symptoms (hazard ratio 845 (Table I) . Radical radiation therapy as the only local treatment adversely affected the local control rate (HR = 3.46, 95% CI = 1.6 to 7.46, p = 0.002), whereas a WBC of >11 · 10 9 /L was associated with a slightly inferior local control rate (HR = 1.98, 95% CI = 0.91 to 4.29, p = 0.08) (see Appendix).
Group with Localized Disease
Univariate analysis of the subgroup of patients without metastasis showed that a WBC of >11 · 10 9 /L (HR = 2.51, 95% CI = 1.32 to 4.75, p = 0.005) adversely affected event-free survival, while a tumor of skeletal origin (HR = 0.17, 95% CI = 0.02 to 1.23, p = 0.08) was associated with a slightly inferior event-free survival rate (see Appendix). None of the factors significantly predicted overall survival, although male sex (HR = 0.4, 95% CI = 0.15 to 1.09, p = 0.07) and a WBC of >11 · 10 9 /L (HR = 2.32, 95% CI = 0.98 to 5.51, p = 0.06) predicted a slightly inferior overall survival rate (see Appendix). A WBC of >11 · 10 9 /L (HR = 3.09, 95% CI = 1.19 to 8, p = 0.02) and radical radiation therapy as the only local treatment (HR = 2.5, 95% CI = 1.01 to 6.16, p = 0.05) predicted a high local control failure rate (see Appendix). The five-year event-free survival (EFS) rate in the total cohort (n = 158) was 36.4% ± 6.4% for the patients with localized disease (localized group) compared with 8.9% ± 4.5% for the metastatic group. Fig. 2-B The five-year overall survival (OS) rate in the total cohort (n = 158) was 57.6% ± 7.4% for the localized group compared with 21.1% ± 8.8% for the metastatic group. Fig. 2 -C The five-year local failure rate was 31.2% ± 8.8% for the patients who underwent surgery with or without postoperative radiation therapy (RT) compared with 63.8% ± 9.8% for those who received radical radiation therapy only in the whole cohort (n = 98). Fig. 2-D The five-year overall survival rate in the total cohort (n = 158) was 52.2% ± 7.6% for the localized group compared with 12.7% ± 6.3% for the metastatic group after exclusion of patients whose survival status could not be assessed (n = 65).
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OUTCOMES A N D P RO G N O S T I C FACTORS F O R EWING-FAMILY T U M O R S O F T H E EXTREMITIES
Multivariate Analysis of Prognostic Factors
Entire Cohort
In multivariate analysis, metastasis emerged as an independent prognostic factor with an adverse effect on event-free survival (HR = 2.21, 95% CI = 1.14 to 4.34, p = 0.02) as well as on overall survival (HR = 2.43, 95% CI = 1.09 to 5.4, p = 0.03) (Table II) (Figs. 2-A and 2-B). Radical radiation therapy as local treatment adversely affected the local control rate (HR = 3.85, 95% CI = 1.74 to 8.54, p = 0.001) (Fig. 2-C) .
Group with Localized Disease
Multivariate analysis showed a WBC of >11 · 10 9 /L (HR = 2.51, 95% CI = 1.32 to 4.75, p = 0.005) to adversely affect event-free survival in the subgroup with localized disease, while no factor predicted overall survival in that group (Table II) ( Fig. 3-A) . A WBC of >11 · 10 9 /L (HR = 3.05, 95% CI = 1.18 to 7.9, p = 0.02) and radical radiation therapy (HR = 2.7, 95% CI = 1.07 to 6.82, p = 0.04) were associated with a high rate of failure of local control in the multivariate analysis of patients with localized disease (Table II) (Figs. 3-B and 3C ).
Analysis After Exclusion of Patients for Whom Overall Survival Could Not Be Assessed
After exclusion of the patients whose final survival status could not be assessed (n = 65), the presence of metastasis (HR = 2.8, 95% CI = 1.32 to 4.8, p = 0.01) continued to be the factor adversely affecting overall survival in the whole group (Table II) ( Fig. 2-D) and a WBC of >11 · 10 9 /L (HR = 3.5, 95% CI = 1.9 to 5.3, p = 0.005) predicted an inferior overall survival rate for patients without metastases (Table II) (Fig. 3-D) . Fig . 3 -A The five-year event-free survival (EFS) rate in the group with localized disease (n = 87) was 46.8% ± 7.1% for patients with a WBC of £11 · 10 9 /L compared with 6.9% ± 6.6% for those with a WBC of >11 · 10 9 /L. Fig 3-B The five-year local failure rate in the group with localized disease (n = 67) was 29.5% ± 7.9% for patients with a WBC of £11· 10 9 /L compared with 83.8% ± 14.4% for those with a WBC of >11 · 10 9 /L. Fig. 3 -C The five-year local failure rate was 36.4% ± 9.9% for the patients who underwent surgery with or without postoperative radiation therapy (RT) compared with 54.6% ± 13% for those who received radical radiation therapy only in the group with localized disease (n = 68). Fig. 3 -D The five-year overall survival (OS) rate in the group with localized disease (n = 89) was 63.4% ± 8% for patients with a WBC of £11 · 10 9 /L compared with 11.1% ± 10.5% for those with a WBC of >11 · 10 9 /L after exclusion of patients whose survival status could not be assessed (n = 32).
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T Discussion W e report the outcomes in 158 patients who underwent combined-modality treatment of a Ewing-family tumor in an extremity. Extremity Ewing-family tumor constituted 42% of all Ewing-family tumors in our cohort, a finding similar to the previously published prevalences of 36% to 56% [1] [2] [3] [4] [5] [6] [7] . The reported prevalence of metastasis at presentation for patients with a Ewing-family tumor is 17% to 29% 1,4-6 . In our cohort, more than half presented with a tumor diameter of >8 cm and a duration of symptoms of more than four months, and 44% had metastasis at initial presentation, suggesting delayed presentation and high tumor burden.
Patients who received radical radiation therapy as local treatment had significantly inferior event-free survival and local control rates compared with patients who underwent surgery, regardless of whether the data were analyzed for the group with or the group without metastasis at baseline (Table I and Appendix). The group that underwent radical radiation therapy had had a higher prevalence of metastasis at presentation compared with the patients who underwent surgery (54% versus 14%, p < 0.001). In the group without metastasis (n = 68), those who received radical radiation therapy (n = 19) did not differ from those who underwent surgery (n = 49) with regard to baseline tumor diameter (p = 0.8), tumor site (p = 0.32), or response to neoadjuvant chemotherapy (p = 0.1). The analysis suggests that those who received radical radiation therapy did not necessarily have poorly responding disease and did not have any adverse baseline tumor characteristics, and yet they had worse event-free survival and local control rates (see Appendix). Thus, even if an extremity Ewing-family tumor shows a good response to neoadjuvant chemotherapy, an attempt should be made to perform a surgical resection.
In the group that underwent surgical resection after neoadjuvant chemotherapy, we found no difference in fiveyear event-free survival and overall survival rates between those who received adjuvant radiation therapy and those who did not; the event-free survival rate was 39.7% ± 9.3% and 56.2% ± 13.6%, respectively (log rank p = 0.17), and the overall survival rate was 68.7% ± 9.7% and 61.3% ± 15.2%, respectively (log rank p = 0.83). In the group with localized disease, forty-four of forty-nine patients who underwent surgical resection had tissue blocks reviewed for histological response to neoadjuvant chemotherapy (blocks were not available for the other five). There was no difference between the group that received adjuvant radiation therapy and the group that did not with regard to the percentage of patients with residual tumor after neoadjuvant chemotherapy (nine of thirteen versus seventeen of thirty-one, p = 0.38) or a poor histological response (necrosis of <90% of the resected specimen) (six of thirteen versus nine of thirty-one, p = 0.43); however, the prevalence of tumor in the surgical margins was higher in the adjuvant radiation therapy group (four of thirteen versus zero of thirty-one, p = 0.002). It is difficult to evaluate the role of radiation therapy in such situations, but these limited data suggest that those who have no residual tumor in the resected specimen (meaning a complete response to chemotherapy as seen on pathological assessment) can perhaps avoid radiation therapy.
A high baseline WBC (>11 · 10 9 /L) was an independent predictor of worse event-free survival and local control rates in the group with localized disease. This observation has not been made in the previous published literature on Ewing-family tumors, to our knowledge. Notably, there was no difference in systemic symptoms (p = 0.43) or tumor location (p = 0.92) between groups with high or normal WBC, but the median tumor size was slightly higher in the former group (11.3 cm compared with 8.8 cm, p = 0.08).
Limitations of our study include the lack of evaluation of translocation (EWS-FLI) at diagnosis even though all patients were evaluated with extensive histological and immunohistochemistry assessments. Furthermore, approximately 20% of our patients were lost to follow-up during therapy so the final survival status could be not ascertained for them.
In conclusion, our data suggest that surgical resection of the primary tumor after neoadjuvant chemotherapy leads to superior results, and that radical radiation therapy alone results in poor local control rates. Patients presenting without metastasis but with a high baseline WBC had inferior event-free survival and local control rates on multivariate analysis and may merit more aggressive therapy.
